EMC易倍

RESEARCH AND PRODUCTION
RESEARCH AND PRODUCTION

Core technology

We have a comprehensive full process research and development platform and a self built production base, which can continuously carry out innovative drug research and development in the long term and efficiently promote clinical development.

Universal Off-the-Shelf in vivo CAR-T Cell Therapy Technology

The company's proprietary universal off-the-shelf in vivo CAR-T technology requires no lymphodepletion, no ex vivo expansion or genetic engineering of T cells, greatly simplifying the manufacturing process. The technology offers strong cell fitness/stemness, prolonged in vivo persistence, enhanced targeting specificity, and improved precision and safety. Through standardized vector manufacturing and preparation, costs are significantly reduced, yielding substantial commercial value.

170070080676
170070060837

Next-Generation Autologous CAR-T Cell Therapy Technology

The company's proprietary next-generation autologous CAR-T features a unique CAR construct conferring superior proliferative capacity and anti-exhaustion properties, with a mild onset profile and prolonged in vivo persistence. It can overcome the immunosuppressive effects of the solid tumor microenvironment and kill tumor cells more effectively. The products are manufactured using the company's globally pioneering scalable high-purity retrovirus, delivering higher purity and efficacy, enhanced safety, low production costs, and competitive market pricing. It is expected to be included in national medical insurance, presenting substantial commercial value.

Globally Pioneering Scalable High-Purity Retrovirus Vector Technology

The company holds independent intellectual property rights for the globally pioneering scalable high-purity retrovirus purification process. The high-purity retrovirus enables transduction to produce products with higher purity and greater safety, at lower production costs and with highly competitive commercial pricing.

170070069984
169742635183

Novel Dendritic Cell (DC) Tumor Vaccine Technology

Dendritic cells (DCs) are the most potent professional antigen-presenting cells in vivo, responsible for capturing and processing tumor antigens and presenting them to T lymphocytes, which constitutes a critical step in initiating antigen-specific anti-tumor immune responses.

The company's proprietary DC tumor vaccine is derived from autologous peripheral blood mononuclear cells, which are ex vivo induced to differentiate into DCs. These DCs are then loaded with specific tumor antigens and matured into sensitized DC tumor vaccines, which are reinfused back into the patient. Following reinfusion, the sensitized DCs migrate to lymph nodes and present tumor antigen information to T cells, thereby activating antigen-specific anti-tumor immune responses.

Gene-Modified Stem Cell Therapy for Monogenic Inherited Diseases

Autologous hematopoietic stem cells are collected and ex vivo modified via viral vector-mediated delivery of functional genes, or corrected for pathogenic mutations using gene-editing tools. Following myeloablative conditioning, the corrected stem cells are reinfused back into the patient, allowing the corrected stem cells to engraft in the bone marrow and continuously produce progeny cells with normal function, thereby correcting the genetic defect at its root.


17007006792
【网站地图】